Limitations of current therapies, the potential for alternative drugs and new therapeutic options are also discussed. Antibiotic combinations are reviewed as well as an analysis of pharmacokinetic and pharmacodynamic parameters to optimize P. Clinical approaches to patients with bacteremia, ventilator-associated pneumonia, urinary tract infections and skin soft tissue infections are discussed. aeruginosa is a pathogen presenting a large genome, and it can develop a large number of factors associated with antibiotic resistance involving almost all classes of antibiotics. The review also looks at the mechanisms associated with resistance – P. Many studies have been performed to evaluate the risk factors for resistance and the potential consequences on mortality and attributable mortality. aeruginosa antimicrobial resistance and infection management will be addressed. Diverse strategies range from killing (new antibiotics) to disarming (antivirulence) the pathogen. Therefore, a vast number of approaches to develop novel anti-infectives is currently pursued.
The major problem leading to high mortality lies in the appearance of drug-resistant strains.
Infections with Pseudomonas aeruginosa have become a real concern in hospital-acquired infections, especially in critically ill and immunocompromised patients.
0 kommentar(er)
